CMS will post 2027 Medicare Advantage Star Ratings on or around October 8. A contract falling from 4.0 to 3.5 stars loses quality bonus eligibility for 2028, but the ratings release changes nothing about the coverage standard applicable to a current authorization or appeal.
On or around October 8, CMS will post the 2027 Medicare Advantage Star Ratings. One week later, on October 15, the Annual Enrollment Period opens and beneficiaries begin shopping plans, with Star Ratings available in Medicare Plan Finder for rated plans and contracts in their service area. The timing allows beneficiaries to see plan quality information before choosing 2027 coverage. Understanding what the October 8 release actually sets in motion, and what it does not, matters for anyone who sits between a plan's financial incentives and a patient's authorization.
The October 8 posting does two separate things that operate on entirely different timelines and affect entirely different people.
The first is a consumer disclosure event. CMS publishes Star Ratings on Medicare.gov roughly one week before AEP opens, giving beneficiaries a rating signal before they lock in coverage for the following year. A plan that drops from 4.0 to 3.5 stars will carry that mark into the enrollment season starting October 15. A rating decline can affect the quality signal members see while comparing coverage during AEP, even when a plan's premium, network, and benefit design were set earlier in the bid cycle.
The second is a quality bonus payment event, and it operates on a slower timetable. The 2027 Star Ratings posted in October 2026 establish quality-bonus eligibility for payment year 2028. The financial consequence does not change a current benefit or authorization decision, but it becomes relevant when plans develop their 2028 bids and benefit packages for submission in June 2027.
The threshold that determines quality bonus eligibility is 4.0 stars. In general, contracts at 4.0 stars or above qualify for a quality bonus payment; the size of the benchmark increase can vary, including under the statutory double-bonus rules in qualifying counties. Contracts below 4.0 stars do not receive the quality bonus. There is no bonus penalty for low performers as such: the consequence is simply the absence of the bonus. A separate consistently low-performing plan framework applies to contracts that receive fewer than three stars for three consecutive years. CMS may flag those contracts for beneficiaries and retains authority to impose consequences, including potential termination in specified circumstances; a three-year low-rating history does not itself mean automatic termination.
A contract dropping from 4.0 to 3.5 stars crosses the threshold in the wrong direction. It moves from bonus-eligible to non-eligible, with the financial impact landing in 2028 payment year calculations. For qualifying contracts, the quality bonus payment increases the applicable county benchmark. The contract's Star Rating also affects the rebate percentage: generally 50% below 4.0 stars, 65% at 4.0 or 4.5 stars, and 70% at 5.0 stars. Together, those benchmark and rebate effects shape the resources available for the subsequent year's premium, cost-sharing, supplemental benefits, and margin. Actual financial impact varies by county benchmark, bid level, enrollment, plan type, and whether the contract qualifies for a double bonus in an eligible county. A 4.0-to-3.5 decline therefore changes the resources a plan may have available for its 2028 bid and benefit design, even though it does not change a patient's current coverage standard.
Quality bonus payments and the rebate percentage attached to the rating shape what a plan can fund in its 2028 bid, which in turn sets the outer edge of the 2028 benefit package. A contract receiving a disappointing October 2026 rating has about eight months before the June 2027 bid deadline to incorporate the loss of bonus eligibility into its 2028 pricing, benefit, network, and supplemental-benefit assumptions.
Earlier this September, CMS released draft cutpoints to plans as part of the preview process that precedes the official October release. Draft-preview analysis reported a more challenging cutpoint environment for some 2027 measures. CMS's final technical materials accompanying the October release should be the source of record for any numerical claim about how many cutpoints moved up, down, or remained unchanged.
Star-measure cut points are calculated using CMS's measure-specific methodology, which incorporates contract performance distributions and can shift as industry performance changes. The practical result is that improvement across the market can raise the performance needed to earn a given measure-level Star Rating. CMS should publish the final 2027 technical materials with the October release; use those materials, rather than draft-preview analysis, for any final numerical claim about cutpoint movement.
Three measures are removed beginning with the 2027 Star Ratings: Care for Older Adults-Pain Assessment, Medication Reconciliation Post-Discharge, and the Medication Therapy Management Program Completion Rate for Comprehensive Medication Review. CMS materials identify the Medication Therapy Management Program Completion Rate for Comprehensive Medication Review as a display-page measure for measurement years 2025 and 2026, returning as a new measure for the 2029 Star Ratings. The CY2027 MA and Part D final rule separately finalized removal of 11 additional measures, with rating-year effects beginning in later cycles; do not treat those 11 removals as changes to the October 2026 ratings release.
The 2026 litigation deserves attention, but its timing should be kept separate from the October 2026 release. In May 2026, a federal court ruled that CMS had improperly included disputed measures in Clover Health's 2026 Star Rating calculation and ordered a recalculation. CMS subsequently conducted a limited voluntary recalculation of certain 2027 Quality Bonus Payment ratings, which are based on 2026 Star Ratings, and said it would change ratings only where the recalculation produced a higher QBP rating. Elevance, SCAN, and Alignment have challenged aspects of CMS's approach, including whether the agency applied the Clover remedy consistently across contracts. Those disputes concern 2026 Star Ratings and 2027 payment-year bonus ratings; they do not establish that the 2027 Star Ratings scheduled for posting in October 2026 will be recalculated.
The October 8 release does not amend NCDs, LCDs, or any plan's current medical policy. It does not alter the evidentiary standard applicable to a pending authorization or an active appeal. A Star Rating does not expand a plan's authority to apply utilization-management or coverage criteria. Any criteria used must comply with applicable Medicare coverage requirements and CMS rules governing MA utilization management.
The coverage standard for an individual authorization comes from Medicare statutes, regulations, national and local coverage determinations where applicable, original-Medicare coverage rules, and the plan's publicly available coverage criteria. MA organizations must furnish covered benefits in accordance with applicable Original Medicare coverage rules and CMS requirements governing MA coverage determinations and utilization management. A contract's Star Rating is not a coverage criterion and does not alter that analysis. A peer-to-peer is not a forum where a plan physician can or should invoke a rating decline as a basis for denial. The rating has no bearing on whether a particular service is covered for a particular patient. Any individual denial should be evaluated against the patient's clinical record, the requested service, applicable Medicare coverage requirements, and the plan's published criteria.
It is worth being explicit about causation. There is no established pattern demonstrating that Star Rating declines translate directly or immediately into tighter utilization management. A plan's response to a rating decline could take several forms: adjustments to its 2028 bid, network strategy changes, increased investment in quality improvement programs, enhanced attention to documentation and care-gap closure, or coding strategy shifts. Presuming that a specific contract's UM decisions were driven by a rating number, without evidence that the plan actually changed its criteria, is not a sustainable clinical or legal argument, and it should not be used as one.
The appropriate forward-looking questions concern future plan-year design and provider operations, not whether a pending authorization should be decided differently because a rating was posted.
Contracts that lose quality bonus eligibility will have constrained resources for benefit design. That could translate to benefit reductions or network changes in 2028 plans. Watch for premium, supplemental-benefit, network, and service-area changes when 2028 plan materials become available during the 2027 annual enrollment season. Before then, monitor public plan communications, earnings disclosures, and provider notices for signs of product or network repositioning.
Clinical policy updates are a separate track. Plans issue updated medical policies through their plan-year documents and mid-year bulletins. A policy that becomes stricter in 2028 should be documented in those published materials and applied consistently. If a plan changes authorization requirements or clinical criteria, the change should be documented in an applicable policy, authorization list, provider manual, bulletin, portal notice, or other formal plan communication and should be traceable to a stated clinical or coverage rationale. Undocumented criterion shifts applied inconsistently are a compliance problem for the plan, not a gray zone for the reviewing physician.
Monitor operational notices from plans and delegated entities for changes in authorization portals, submission channels, decision contacts, delegated-review organizations, or escalation procedures. Do not infer a change in coverage criteria until the plan publishes a revised policy or communicates a documented operational change.
Plans with performance gaps in HEDIS, CAHPS, medication adherence, or care-coordination measures may increase provider outreach related to documentation, gap closure, medication adherence, and preventive-care follow-up. Treat these contacts as quality-improvement activity, not as a change in a patient's coverage standard.
A 4.0-to-3.5 Star Rating decline can materially affect a contract's 2028 quality-bonus eligibility and bid strategy. It does not change the Medicare coverage standard governing a pending authorization, appeal, or peer-to-peer. For physician advisors and utilization-review leaders, the disciplined response is to keep those questions separate: evaluate every case against the patient's record, applicable Medicare coverage requirements, and the plan's published criteria; monitor future benefit, network, policy, and workflow changes when they are actually documented; and do not attribute an individual denial to a Star Rating without evidence of an actual policy or process change.
Sources: CMS 2027 MA/Part D landscape materials (expected October 8 release timing); CMS 2027 Star Ratings measures-and-weights document (three 2027 measure removals); CMS CY2027 MA/Part D final-rule fact sheet (later 11-measure removals); CMS QBP materials and annual rate announcement (4.0-star threshold and bid-year mechanics); Healthcare Dive, "Half of Medicare Advantage stars thresholds harder to reach in 2027," September 10, 2026 (Newton Smith Group draft analysis); RISE Health, "2027 Star Ratings release: what the October posting sets in motion," September 18, 2026. [verify: October 8 release date -- confirm against CMS official posting when it goes live; verify Clover court order date and CMS recalculation memorandum]
Discover how Addie helps health systems, post-acute providers, and payers improve throughput, reduce avoidable days, and deliver better transitions of care.
Get Started
